Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy

20 Mar 2025

Abstract excerpt

• Phase 2 trials are underway for zolbetuximab therapy in pancreatic adenocarcinoma. • Claudin 18 (43–14A clone) immunohistochemistry determines zolbetuximab eligibility. • Claudin 18 expression with 43–14A is unclear in pancreatic adenocarcinoma. • We found 32.5 % of PDACs express Claudin 18 using the 43–14A antibody clone. • Claudin 18 expression associates with lower grade and better median overall survival....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Barrier Structure and Function Studies
Share to Caveolin-1 and cellular processes
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40117781
DOI: 10.1016/j.tranon.2025.102362

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapyPMID 40117781Read ↗

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. PishvaianSemantic proximity Read ↗

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomesSemantic proximity Read ↗

Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody DevelopmentSemantic proximity Read ↗

Identification of CLDN18 as a potential diagnostic biomarker and therapeutic target for pancreatic cancer based on multiomic analysisSemantic proximity Read ↗

The claudin gene family: expression in normal and neoplastic tissuesSemantic proximity Read ↗

TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Prognostic significance of Claudin18.2 expression in patients with gastric cancer: Insights from original research and meta-analysisSemantic proximity Read ↗

Treatment Selection for Patients with HER2-Negative Metastatic Gastric Cancer Expressing Claudin 18.2 and PD-L1Semantic proximity Read ↗

Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypesSemantic proximity Read ↗

Immunohistochemical expression of Claudin18.2 in borderline and malignant gynecologic tumors: Results from a pilot studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.